UBS Asset Management Americas Inc. cut its position in shares of Chimerix Inc. (NASDAQ:CMRX) by 69.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 991,481 shares of the biopharmaceutical company’s stock after selling 2,264,710 shares during the period. UBS Asset Management Americas Inc. owned 2.15% of Chimerix worth $3,897,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Royal Bank of Canada increased its stake in shares of Chimerix by 9,017.0% in the first quarter. Royal Bank of Canada now owns 24,160 shares of the biopharmaceutical company’s stock worth $123,000 after buying an additional 23,895 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Chimerix during the second quarter worth $159,000. Alps Advisors Inc. increased its stake in shares of Chimerix by 25.1% in the second quarter. Alps Advisors Inc. now owns 64,919 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 13,023 shares during the period. Sabby Management LLC bought a new stake in shares of Chimerix during the first quarter worth $274,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Chimerix during the second quarter worth $322,000. Institutional investors and hedge funds own 66.12% of the company’s stock.
Chimerix Inc. (NASDAQ:CMRX) traded down 0.18% during midday trading on Friday, reaching $5.54. 463,158 shares of the company’s stock traded hands. The company’s market cap is $256.03 million. The stock has a 50-day moving average of $5.00 and a 200 day moving average of $4.78. Chimerix Inc. has a 52-week low of $3.50 and a 52-week high of $43.37.
Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $0.12. Chimerix had a negative net margin of 1,356.50% and a negative return on equity of 34.75%. The business had revenue of $1.80 million for the quarter, compared to the consensus estimate of $1.98 million. On average, analysts anticipate that Chimerix Inc. will post ($1.78) earnings per share for the current fiscal year.
A number of research firms have recently commented on CMRX. Zacks Investment Research downgraded shares of Chimerix from a “buy” rating to a “hold” rating in a report on Thursday, August 11th. Piper Jaffray Cos. set a $12.00 price objective on shares of Chimerix and gave the stock a “buy” rating in a report on Thursday, August 18th. FBR & Co reduced their price objective on shares of Chimerix from $9.00 to $8.00 and set a “mkt perform” rating for the company in a report on Tuesday, August 9th. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $7.00 price objective on shares of Chimerix in a report on Tuesday, August 9th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. Chimerix has a consensus rating of “Hold” and a consensus target price of $12.28.
In other Chimerix news, insider M Michelle Berrey purchased 22,417 shares of the firm’s stock in a transaction that occurred on Monday, August 29th. The shares were acquired at an average cost of $4.47 per share, for a total transaction of $100,203.99. Following the completion of the purchase, the insider now owns 281,238 shares of the company’s stock, valued at approximately $1,257,133.86. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director John M. Leonard sold 5,000 shares of the company’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $5.03, for a total transaction of $25,150.00. The disclosure for this sale can be found here. 10.50% of the stock is currently owned by corporate insiders.
Chimerix Company Profile
Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.
Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix Inc. (NASDAQ:CMRX).
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.